Weight Loss After Ovarian Cancer Treatment in South Africa
Ovarian cancer and its treatment create a complex weight landscape: some women gain weight during chemotherapy due to steroids and inactivity, others lose weight dramatically from ascites, nausea, and surgery. Surgical menopause happens overnight rather than over years. And the bowel changes from debulking surgery affect digestion for months to years. This guide is specifically for ovarian cancer survivors in South Africa, navigating weight management in survivorship.
Medical disclaimer: This article is for ovarian cancer survivors post-treatment. It does not replace your oncologist's, gynaecological oncologist's, or dietitian's advice. Weight management decisions post-cancer should always involve your care team, particularly regarding HRT eligibility (which depends on your specific tumour type) and the timing and nature of exercise after surgery.
Ovarian Cancer in South Africa
Ovarian cancer is the third most common gynaecological cancer in South Africa after cervical and endometrial cancer, with approximately 2,000–2,500 new diagnoses per year. It is often called the "silent killer" because it frequently presents at an advanced stage (III or IV) — by the time symptoms like bloating, abdominal fullness, and urinary frequency become noticeable, the disease has often spread beyond the ovaries.
Survival rates have improved with better surgical techniques and the addition of bevacizumab (Avastin) and PARP inhibitors (olaparib/niraparib) for maintenance therapy. Many South African women are now living years into survivorship with ovarian cancer — and the long-term effects of treatment on weight and nutrition deserve proper attention.
Types of Ovarian Cancer and Weight Implications
Understanding your tumour type matters for weight management:
| Type | Prevalence | HRT for surgical menopause? | Oestrogen-sensitive? |
|---|
| High-grade serous (HGSOC) | ~70% of all ovarian cancer | Generally yes — discuss with oncologist | Not primarily |
| Endometrioid ovarian cancer | ~10% | Discuss with oncologist | Some oestrogen sensitivity |
| Clear cell ovarian cancer | ~10% | Usually acceptable — discuss | Minimal |
| Mucinous ovarian cancer | ~3% | Usually acceptable — discuss | Minimal |
| Granulosa cell tumour (sex cord-stromal) | ~5% | Contraindicated — tumour is oestrogen-producing | Yes — strongly |
| Borderline (low malignant potential) | ~15% | Usually acceptable — discuss | Minimal |
What Causes Weight Changes After Ovarian Cancer Treatment?
1. Surgical Menopause
Standard treatment for most ovarian cancer involves bilateral salpingo-oophorectomy (BSO) — removal of both ovaries and fallopian tubes. This causes immediate, abrupt surgical menopause in premenopausal women, with consequences more severe than natural menopause:
- Rapid fat redistribution: fat migrates from hips and thighs to the abdomen within months
- Muscle mass loss: oestrogen plays a role in muscle protein synthesis; its loss accelerates sarcopenia
- Reduced metabolic rate: muscle loss + hormonal changes reduce how many calories you burn at rest
- Hot flashes and night sweats: disrupt sleep, which worsens appetite regulation hormones (ghrelin and leptin)
- Increased appetite: some women experience a significant increase in appetite after oophorectomy
2. Corticosteroids With Chemotherapy
The standard first-line chemotherapy for ovarian cancer — carboplatin + paclitaxel (Taxol) — requires dexamethasone (a corticosteroid) as a pre-medication to prevent allergic reactions to paclitaxel. Dexamethasone is given at high doses before each cycle (typically 6 cycles, 3-weekly):
- Causes significant fluid retention and apparent weight gain (2–4kg per cycle in some women)
- Increases blood sugar and appetite, particularly for carbohydrates and sweet foods
- Promotes central (abdominal) fat distribution
- Effects reduce between cycles but accumulate over the treatment course
3. Ascites and Weight Confusion
Ascites — fluid accumulation in the abdominal cavity — is common in advanced ovarian cancer and can add substantial scale weight (sometimes 5–15kg) that is not fat. This weight disappears when ascites resolves with treatment or is drained by paracentesis. However, malnutrition is common alongside ascites:
- Ascites compresses the stomach, causing early satiety and dramatically reducing food intake
- Cancer cachexia (cancer-driven muscle wasting) occurs independently of food intake
- The combination of reduced intake + muscle wasting means real lean mass loss even when scale weight appears high
If you were heavier before treatment and have lost weight: the loss may be a mix of healthy fat loss and unhealthy muscle loss. Body composition assessment (rather than just scale weight) is the most useful measure in survivorship.
4. Surgery and Bowel Changes
Ovarian cancer debulking surgery is major abdominal surgery that can involve bowel resection, adhesion formation, and significant changes to intestinal anatomy. Consequences for nutrition and exercise:
- Adhesions: scar tissue can cause intermittent bowel obstruction, bloating, and discomfort with certain foods and exercise positions
- Bowel resection: if part of the bowel was removed, absorption of certain nutrients may be permanently altered
- Altered anatomy: changes in the pelvic anatomy may affect core exercise comfort
- Recovery time: major debulking requires 6–12 weeks recovery before significant exercise resumption
Nutrition Priorities in Ovarian Cancer Survivorship
Rebuild Muscle First, Lose Fat Second
The most common post-ovarian cancer body composition problem is not excess fat — it is loss of muscle mass (sarcopenia) from cancer, treatment, reduced activity, and surgical menopause. Prioritise muscle preservation and rebuilding before aggressive fat loss:
- Protein: 1.0–1.2g/kg body weight/day minimum — the single most important nutritional intervention for muscle preservation. Eggs (complete protein, affordable at R35–R60/dozen), chicken, fish (pilchards, hake), amasi, lentils, chickpeas
- Leucine: the amino acid most potent for stimulating muscle protein synthesis; found in eggs, dairy, chicken, beef, and whey protein. Include a leucine-rich protein source at each main meal
- Resistance training + protein together: the combination is far more effective than either alone for building muscle in post-menopause
- Do not go below 1,400 kcal/day without dietitian supervision — severe restriction accelerates muscle loss and bone loss in surgical menopause
Managing Chemotherapy-Related Nutritional Deficiencies
Platinum-based chemotherapy causes several lasting nutritional effects:
- Peripheral neuropathy: numbness and tingling in hands and feet (paclitaxel-related); vitamin B12 deficiency worsens neuropathy — ensure adequate B12 (meat, eggs, dairy, or supplement). Consider B complex supplement
- Taste changes: metallic taste, food aversions; often improve within 3–6 months post-treatment. Marinating meat, using fresh herbs, and serving food at cooler temperatures can help
- Kidney function: carboplatin is nephrotoxic; adequate hydration (2+ litres daily) supports kidney protection
- Magnesium: platinum agents deplete magnesium; fatigue, muscle cramps, and poor sleep may be magnesium-related. Magnesium-rich foods: nuts, seeds, dark chocolate, whole grains, dark leafy greens
Calcium and Bone Health
Surgical menopause dramatically increases osteoporosis risk. With ovarian cancer treatment, bone health is a priority:
- Target 1,000–1,200mg calcium daily from food: amasi, lactose-free milk, canned sardines and pilchards (eat the bones), fortified plant milks, calcium-set tofu
- Vitamin D: 1,000–2,000 IU/day supplement; crucial for calcium absorption; check blood levels
- Weight-bearing exercise: walking and resistance training stimulate bone formation
- Avoid smoking and limit alcohol: both accelerate bone loss
- Request DEXA bone density scan from your oncologist — likely within 2 years of surgical menopause
Anti-Cancer Diet Principles for Ovarian Cancer Survivors
While no diet can guarantee prevention of recurrence, certain dietary patterns are associated with better cancer outcomes in observational research:
| Dietary Pattern | Evidence Strength | Key SA Foods |
|---|
| Mediterranean diet | Strong — associated with reduced ovarian cancer risk and better survival | Olive oil, pilchards, legumes, morogo, tomatoes, rooibos |
| High vegetable and fruit intake | Moderate-strong | Morogo, spinach, tomatoes, sweet potato, guava, mango |
| Low ultra-processed food | Emerging strong evidence | Avoid pre-packaged snacks, instant noodles, reconstituted meats |
| Low refined carbohydrate / low glycaemic | Moderate — insulin pathway reduction | Oats, sweet potato, legumes instead of white bread/rice |
| High omega-3 fatty acids | Moderate — anti-inflammatory | Canned pilchards, sardines, mackerel (affordable, SA-available) |
| Fermented foods (gut microbiome) | Emerging | Amasi, plain yoghurt, kefir, fermented vegetables |
Specific Foods With Ovarian Cancer Relevance
- Cruciferous vegetables (broccoli, cauliflower, Brussels sprouts, cabbage) — contain sulforaphane and indole-3-carbinol; some in vitro evidence for ovarian cancer cell effects; general anti-cancer properties
- Tomatoes — lycopene; some epidemiological association with reduced ovarian cancer risk
- Turmeric (curcumin) — anti-inflammatory; add to food (better absorbed with black pepper and fat); limited but promising pre-clinical evidence
- Green tea (EGCG) — antioxidant; avoid excessive amounts on PARP inhibitors (discuss with oncologist)
- Soy foods — conflicting evidence; most current guidelines say moderate consumption (whole soy like tofu and edamame) is safe for most ovarian cancer survivors — not concentrated soy supplements
Supplements and chemotherapy/PARP inhibitors: Do not take high-dose antioxidant supplements (vitamins C, E, selenium) during active chemotherapy without discussing with your oncologist — there is theoretical concern about antioxidants interfering with oxidative damage mechanisms of chemotherapy. In survivorship (not active treatment), supplementation is generally safer but discuss specific supplements with your care team, especially if on maintenance therapy (bevacizumab or PARP inhibitors).
Practical Weight Loss Strategies for Ovarian Cancer Survivors
Sample Day of Eating — Post-Ovarian Cancer (Muscle-Protective, Anti-Inflammatory):
Breakfast: 2-egg omelette with spinach and tomato + 1 slice whole-grain toast + rooibos tea with full-cream milk — ~400 kcal, high protein
Mid-morning: Plain amasi (250ml) + fresh mango or berries — ~200 kcal, calcium, probiotics
Lunch: Lentil and vegetable soup + 1 slice seed bread + avocado (small) — ~450 kcal, plant protein, anti-inflammatory
Afternoon snack: Handful of walnuts + green tea or rooibos — ~200 kcal, omega-3
Dinner: Baked hake or grilled chicken thigh (skin off) + roasted sweet potato + large serving of morogo or broccoli — ~500 kcal, protein, calcium, cruciferous vegetables
Evening (if needed): Small bowl of full-cream yoghurt — ~150 kcal, calcium, probiotics
Total: ~1,900 kcal | Protein ~100g | Anti-inflammatory | High in calcium, vitamin D from diet, cruciferous vegetables | Bowel-gentle if adhesions are a concern (cooked, not raw vegetables)
Exercise in Ovarian Cancer Survivorship
Exercise is increasingly recognised as a survival benefit factor across multiple cancer types. For ovarian cancer survivors:
When to Start
- Light walking: often 2–4 weeks post-surgery when wounds are healed
- Resistance training and more vigorous exercise: typically 6–8 weeks post-surgery; confirm with your surgeon
- Avoid abdominal exercises that cause discomfort or pain due to adhesions — listen to your body
Exercise Recommendations
- Resistance training (2–3x/week): the most important exercise for post-surgical-menopause weight management; maintains muscle, boosts metabolism, strengthens bone. Start with resistance bands or light weights — a biokineticist or physiotherapist can design an appropriate programme
- Walking (daily, building to 45–60 minutes): improves cardiovascular health, mood, and bone density; lower injury risk than running
- Swimming: ideal if abdominal adhesions make land exercise uncomfortable; zero joint impact
- Yoga/Pilates: core strength, flexibility, stress management — look for cancer survivor-adapted classes
- Avoid: extreme abdominal crunches if there are adhesion issues; consult your surgeon about any movements that cause pulling sensations in the abdomen
BRCA1/2 Status and Weight Management
Approximately 15–20% of ovarian cancers are related to BRCA1 or BRCA2 gene mutations. If you have a BRCA mutation:
- Your relatives (sisters, daughters) should be offered genetic testing — discuss with your oncologist for a genetic counselling referral
- BRCA status affects surgical decisions (risk-reducing mastectomy discussion for BRCA1/2 carriers) and maintenance treatment choices (PARP inhibitors like olaparib are most effective in BRCA-mutated cancers)
- Weight-related cancer risk: maintaining healthy weight may be particularly important for BRCA carriers who remain at risk of contralateral breast cancer
- Genetic counselling services are available at academic hospitals in Johannesburg, Cape Town, and Durban
South African Resources
- CANSA (Cancer Association of South Africa) — cansa.org.za | Care line: 0800 22 6622 (toll-free) | CANSA Care Centres nationwide with dietitian services and support groups
- Gynaecological Cancers Association of South Africa (GCASA) — peer support and advocacy for ovarian cancer survivors
- ADSA (Association for Dietetics in South Africa) — adsa.org.za — oncology-trained registered dietitians
- Biokinetics Association of SA (BASA) — find a biokineticist experienced in cancer survivorship exercise rehabilitation
- Medical aid: Ovarian cancer treatment falls under the PMB oncology basket — medical aids must cover surgery, chemotherapy, and specialist visits. Maintenance therapy (olaparib, bevacizumab) may require prior authorisation given cost.
- SADAG — sadag.org | 0800 456 789 — mental health support for cancer survivors dealing with anxiety, depression, and grief
FAQ: Ovarian Cancer and Weight Management
Why have I gained weight since completing ovarian cancer treatment?
Multiple treatment effects combine: surgical menopause redistributes fat to the abdomen and reduces metabolic rate; corticosteroids given with carboplatin/paclitaxel promote fat storage and fluid retention; reduced activity during treatment and recovery leads to muscle loss; and cancer-related fatigue persists, limiting exercise. The combination creates a metabolic environment that favours weight gain despite eating normally. HRT (if appropriate for your tumour type), resistance training, and protein prioritisation are the most effective interventions.
Can I take HRT after ovarian cancer?
It depends on your tumour type. For most epithelial ovarian cancers (high-grade serous, clear cell, mucinous), HRT is generally considered acceptable and may significantly improve quality of life and metabolic health. For sex cord-stromal tumours (granulosa cell tumours), which are oestrogen-producing, HRT is generally contraindicated. Always discuss with your gynaecological oncologist before starting HRT — the answer is very often yes, but must be personalised.
Should I follow a special "anti-cancer" diet as an ovarian cancer survivor?
The Mediterranean diet has the strongest evidence base for cancer survivorship outcomes. A diet rich in vegetables (especially cruciferous), fruits, whole grains, legumes, oily fish, and olive oil — while limiting ultra-processed food, refined carbohydrates, red and processed meat, and alcohol — is the most evidence-based overall approach. No single "superfood" or supplement has proven anti-recurrence benefit in isolation.
What weight loss rate is safe for ovarian cancer survivors?
A maximum of 0.5–0.75kg per week is appropriate. More aggressive restriction risks muscle loss (a major problem in surgical menopause), bone loss, nutrient deficiencies, and fatigue that reduces your ability to be active. Prioritise rebuilding muscle through protein and resistance exercise — this improves body composition and metabolism even if scale weight loss is slow.
Sources: CANSA South Africa 2024 | National Cancer Registry SA 2022 | Barnard ME et al, BMC Cancer 2022 | Rock CL et al, CA Cancer J Clin 2022 | Brasky TM et al, Nutrients 2020 | ESMO Ovarian Cancer Clinical Practice Guidelines 2023 | GCASA Patient Guidelines | CDL/PMB Defined Benefits Schedule 2024 | ADSA Oncology Nutrition Practice Guidelines. Last reviewed June 2026.